TE-8105 in Overweight or Obesity

Phase 2, randomised, double-blind trial of TE-8105 in obesity (6 cohorts), sponsored by Immunwork. Primary endpoints: Incidence of treatment-emergent adverse events at 31 weeks and Changes from baseline in clinical laboratory assessments, physical examination findings, vital signs, and electrocardiogram (ECG) values at 31 weeks. Planned start Oct 2026; status: not yet recruiting.